Lithium and clozapine-induced neutropenia/agranulocytosis.
Lithium administration was used in a patient with a clozapine-induced neutropenia and in another with complete agranulocytosis to assess whether lithium could stimulate neutrophil production. In both cases, following lithium administration, the neutrophil count was increased to the normal range within 6 days. In the patient who had presented a neutropenia, clozapine treatment was then reinstated in the presence of lithium and continued without the neutrophil count dropping into the yellow-alert range thereafter.
Blier
P
P
Department of Psychiatry, McGill University, Montréal, Quebec, Canada.
Slater
S
S
Measham
T
T
Koch
M
M
Wiviott
G
G
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced* / Q000188:drug therapy; D018692:Antimanic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D016651:Lithium Carbonate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009494:Neurosyphilis / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy*
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D016651:Lithium Carbonate; D003024:Clozapine